Platelet Compatibility: Looser Rules Than Red Cells
Updated May 2026
Reference summary
Platelets are matched on ABO when supply allows, but ABO-incompatible platelet transfusions are routine when matched supply is unavailable. The five-day shelf life makes platelet supply chronically tight. Patients refractory to standard platelets need HLA-matched platelets from a typed donor pool. This page summarises clinical practice and donation pathways. It is not medical advice. Decisions about transfusion are made by your treating haematology team.
What platelets are and what they do
Platelets (technically thrombocytes) are small, disc-shaped cell fragments derived from megakaryocytes in the bone marrow. They circulate in blood at about 150 to 400 thousand per microlitre and are responsible for the first phase of haemostasis: when a blood vessel is damaged, platelets adhere to the exposed sub-endothelium, change shape, release granule contents that recruit more platelets, and form a primary platelet plug. The coagulation cascade then deposits fibrin on top of this plug to form the definitive clot.
Patients with low platelet counts (thrombocytopenia) or dysfunctional platelets are at risk of bleeding. Spontaneous bleeding becomes a concern below about 20 thousand per microlitre, and serious bleeding becomes likely below 10 thousand per microlitre. Platelet transfusion is the main supportive therapy for these patients.
Common patient groups needing platelet transfusion include those receiving chemotherapy for haematological malignancies (acute leukaemia, lymphoma), patients with aplastic anaemia, patients undergoing stem cell transplantation, and surgical patients with active bleeding and thrombocytopenia. The NICE NG24 guideline on blood transfusion sets out current UK practice on indications and thresholds.
Why ABO matters less for platelets than for red cells
Platelets express ABO antigens on their surface, but at much lower density than red cells. They also carry HLA Class I antigens, which become more clinically important than ABO in the multiply-transfused recipient. The functional consequence is that ABO-incompatible platelet transfusions, while not ideal, are clinically acceptable and routinely used.
The two concerns with ABO-incompatible platelets are reduced platelet count increment (the patient's platelet count rises less after transfusion than a matched product would deliver) and passive transfer of donor anti-A or anti-B antibodies in the suspending plasma. The latter can theoretically cause haemolysis of the recipient's red cells if antibody titres are high. Most blood centres screen high-titre group O donors and avoid using their platelets across ABO incompatibility, or use plasma-reduced platelets for such transfusions.
For routine practice, the order of preference is: identical ABO and Rh, then identical ABO and incompatible Rh (with anti-D prophylaxis for D-negative women of childbearing potential), then ABO compatible (recipient's antibodies will not attack donor antigens), then ABO incompatible. The AABB technical manual and the UK JPAC transfusion guidelines codify this preference order.
The five-day shelf life problem
Platelets are stored at room temperature (20-24 degrees Celsius) with continuous gentle agitation. They cannot be refrigerated like red cells because cooling alters their morphology and reduces post-transfusion survival. Room-temperature storage carries a higher bacterial growth risk than cold storage, which is why platelet products undergo bacterial detection (culture or rapid tests) and have a five-day shelf life from collection. Some centres extend to seven days with additional bacterial screening.
The short shelf life means platelet supply cannot be stockpiled. A blood centre needs continuous platelet collection to meet daily demand. The American Red Cross platelet donor programme and the NHSBT platelet appeal both run continuous campaigns to recruit and retain regular platelet donors.
Frequent platelet donors can give as often as every 7 days (US) or every 28 days (UK) up to a maximum of 24 donations per year (both jurisdictions). One apheresis donation produces an adult therapeutic dose, so each regular donor effectively replaces six to twelve whole-blood donors' worth of platelet supply.
Apheresis vs pooled platelets
Modern blood banks produce platelets in two ways. Apheresis (also called single-donor platelets, SDP) collects an entire adult therapeutic dose from one donor over about 90 minutes. The donor sits with a blood-cell separator that removes platelets and returns red cells, plasma, and saline to the donor. Pooled platelets (also called whole-blood-derived or buffy-coat platelets) combine the platelet fractions from four to six whole-blood donations into a single product.
Apheresis platelets expose the recipient to one donor; pooled platelets expose them to four to six. For patients receiving repeated platelet transfusions over years (such as patients with aplastic anaemia or chronic blood disorders), single-donor exposure reduces the cumulative risk of HLA alloimmunisation and infectious transmission. Most modern haematology programmes therefore favour apheresis platelets where supply allows.
For one-off transfusions in surgical bleeding or acute trauma, the difference matters less, and pooled platelets are widely used.
HLA matching for refractory recipients
About 30 to 40 percent of patients receiving repeated platelet transfusions develop antibodies to HLA antigens. Once these antibodies are present, the recipient's platelet count rises minimally after standard platelet transfusion. The patient is described as platelet refractory due to HLA alloimmunisation.
The clinical response is to match the platelet donor to the recipient's HLA type. This requires a typed donor pool large enough to find a matching donor on demand. The American Red Cross HLA-typed platelet programme and the equivalent NHSBT programme maintain registers of HLA-typed apheresis donors for exactly this purpose. Patients on the refractory list are linked to compatible donors over time.
HLA matching for platelets is graded A through D (A is the closest match) based on antigen overlap. A-grade matches are preferred but B-grade or partial matches are used when A-grade is unavailable.
Donating platelets
Apheresis platelet donation involves a longer appointment than whole blood, typically 90 to 120 minutes. The donor is connected to a blood cell separator, which draws blood, separates platelets, and returns red cells and plasma. The procedure is well tolerated; common side effects are tingling around the mouth from citrate (the anticoagulant) and mild fatigue.
Eligibility is broadly the same as whole blood donation, with a few specific platelet-donation considerations: aspirin and many NSAIDs disable platelets for the lifetime of the platelet (about 7 to 10 days), so recent aspirin or NSAID use defers platelet donation. Adequate platelet count and venous access are checked at each visit.
See our who can donate blood page for general eligibility and our donation intervals page for timing rules across whole blood, platelets, and plasma.